Anne Lodge, Founder

Anne Lodge, Astarte Biologics FounderAnne Lodge received her Ph.D. in Cell and Molecular Biology from the University of Vermont. Her thesis work examined the activation of CD4+ and CD8+ T cells by vascular endothelium and revealed the importance of endothelial cells in triggering organ rejection.

After completing her graduate work, Dr. Lodge received a postdoctoral fellowship from the Multiple Sclerosis Society. The fellowship supported her work at Vanderbilt University in the laboratory of Dr. Subramaniam Sriram. She studied T cells from patients with MS to determine their role in the disease process.

Dr. Lodge then accepted a position with Northwest Biotherapeutics, Inc. in Seattle. She had a number of different roles at the company and contributed to the Investigational New Drug filings for the company’s dendritic cell vaccine. Her expertise in cell-based therapeutics and broad background in immunology led to her founding Astarte Biologics in 2004 to provide immune cell products for research.


Smith J.P.; Lipsky P. E.; Lodge A. Human T cell line assay for evaluating the immunologic identity of glatiramer acetate preparations. Application Number 14/522,521. Filed October 23, 2014.

Shankar G.; Lodge, P.A.; Brunelle, A.N. Quality assays for antigen presenting cells. Application Number 60/379,126. Filed June 14, 2012.

Bosch M. L.; Harris P. C.; Monahan S. J.; Turner A.; Boynton A. L.; Lodge P. A. Tangential flow filtration devices and methods for leukocyte enrichment. Application Number 12/759,552. Patent Number 8,518.636. Filed April 13, 2010.

Bosch M. L.; Lodge P. A.; McEarchern J. A.; Boynton A. L.; Hugenholtz P. G. Tangential flow filtration devices and methods for stem cell enrichment. Application Number 10/992,154. Patent Number 7,790,039. Filed November 18, 2004.

Bosch M. L.; Harris P. C.; Monahan S. J.; Turner A.; Boynton A. L.; Lodge P. A. Tangential flow filtration devices and methods for leukocyte enrichment. Patent Number 7,695,627. Filed June 19, 2003.


Generation and analysis of human T cell lines responsive to Glatiramer Acetate. American Academy of Neurology. 2018.

The COSTIM bioassay: a novel potency assay for dendritic cells. Journal of Immunological Methods. 2004.

Immune monitoring of cancer biotherapy: need for harmonizing biotechnical prowess, practicality, and quality control. Expert Opinion on Biological Therapy. 2002.

Serological cloning of PARIS-1: a new TBC domain-containing, immunogenic tumor antigen from a prostate cancer cell line. Biochemical and Biophysical Research Communications. 2002.

Dendritic cell-based immunotherapy of prostate cancer: immune monitoring phase II clinical trial. Cancer Research. 2000.

Dendritic cell-based immunotherapy for prostate cancer. CA: A Cancer Journal for Clinicians. 1999.

Use of cellular and cytokine adjuvants in the immunotherapy of cancer. Journal of Surgical Oncology. 1998.

Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA). Prostate. 1998.

Dendritic cell-based immunotherapy of prostate cancer. Critical Reviews in Immunology. 1998.

Cancer immunotherapy for prostate cancer. Canadian Journal of Urology. 1997.

The Scientific Foundations of Neurology. 1996.

Regulation of microglial activation by TGF-beta, IL-10, and CSF-1. Journal of Leukocyte Biology . 1996.

Vaccination with peptides from MHC class II beta chain hypervariable region causes allele-specific suppression of EAE. Journal of Neuroimmunology. 1996.

Frequency of MBP and MBP peptide-reactive T cells in the HPRT mutant T-cell population of MS patients. Neurology. 1996.

Myelin basic protein peptide specificity and T-cell receptor gene usage of HPRT mutant T-cell clones in patients with multiple sclerosis. Annals of Neurology. 1994.

T cell subset responses to allogeneic endothelium. Proliferation of CD8+ but not CD4+ lymphocytes. Transplantation. 1993.

A simple method of vascular endothelial cell isolation. Transplantation Proceedings. 1992.

Suppression of a xenogeneic mixed lymphocyte endothelial cell culture with 15-deoxyspergualin. Transplantation Proceedings. 1992.

Biological differences in endothelial cells depending upon organ derivation. Transplantation Proceedings. 1991.

The vascular endothelial cell acts as the primary stimulus of T-lymphocyte proliferation in the in vitro xenogeneic response (XIR). Transplantation Proceedings. 1991.

The role of neutrophils and platelets in a rabbit model of thromboembolic stroke. Stroke. 1991.

Functional diversity in vascular endothelial cells: role in coxsackievirus tropism. Journal of Virology. 1990.

In vitro human versus murine xenogeneic reactions. Transplantation. 1990.

The vascular endothelial cell is central to xenogeneic immune reactivity. Surgery. 1990.

Clinical and experimental aspects of viral myocarditis. Clinical Microbiology Reviews. 1989.

Immunopathogenic mechanisms in experimental picornavirus-induced autoimmunity. Pathology and Immunopathology Research. 1988.

Coxsackievirus B-3 myocarditis. Acute and chronic forms of the disease caused by different immunopathogenic mechanisms. American Journal of Pathology. 1987.

Coxsackievirus B-3 myocarditis. Identification of different pathogenic mechanisms in DBA/2 and Balb/c mice. American Journal of Pathology. 1986.

Immunopathogenesis of experimental Coxsackievirus induced myocarditis: role of autoimmunity. Herz. 1985.

Cardiac injury in myocarditis induced by Coxsackievirus group B, type 3 in Balb/c mice is mediated by Lyt 2 + cytolytic lymphocytes. Cellular Immunology. 1984.

Coxsackievirus B-3 myocarditis in Balb/c mice. Evidence for autoimmunity to myocyte antigens. American Journal of Pathology. 1984.